Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

The randomized STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for the treatment of patients with metastatic castration-resistant prostate cancer.

There was no difference seen in immune parameters when comparing early and delayed enzalutamide. Further, Petrylak said, the prime-boost effect was similar in the two arms.

Anecdotally, Petrylak said, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Petrylak on the Results of the Phase II STRIDE Study